In summary, BRAF mutations appear to occur more frequently in CRC tumours with MSI-high characterised by dMMR, posing as strong OS prognostic factor, but also presence of KRAS mutations in patients proficient in MMR may suggest highest recurrence rate. The gene discussed is KRAS; the disease is neoplasm.